Video

Dr. Jun Discusses Cyptogenic Hepatocellular Carcinoma

Author(s):

Tomi Jun, MD, Stanford University School of Medicine, discusses cryptogenic hepatocellular carcinoma.

Tomi Jun, MD, Stanford University School of Medicine, discusses cryptogenic hepatocellular carcinoma (HCC).

Although viral liver diseases are seen as the predominant risk factor of HCC, Jun says, there is a population of patients with cryptogenic HCC—mostly those with non-alcoholic fatty liver disease.

Although patients with cryptogenic HCC show less cirrhosis than HCC caused by viral diseases such as hepatitis B and C, the rate of long-term survival is worse.

Related Videos
David A. Braun, MD, PhD
Amma Asare, MD, PhD
Anthony V. D'Amico, MD, PhD
Alexandra Drakaki, MD, PhD
Grzegorz S. Nowakowski, MD
Sagar Lonial, MD, FACP
Joshua Linscott, MD, PhD
Yuan Yuan, MD, PhD
John V. Heymach, MD, PhD, chair, Thoracic/Head and Neck Medical Oncology, and the David Bruton Endowed Chair in Cancer Research, The University of Texas MD Anderson Cancer Center
Komal Jhaveri, MD, FACP